Direct C-4 Alkylation of Quinazoline N-Oxides with Ethers viaOxidative Cross-Coupling Reaction under Transition-Metal-free Conditions

Qin Yang, Minhao Lou, Zhijian Yin, Zhihong Deng, Qiuping Ding,*YiyuanPeng* ^aKey Laboratory of Small Functional Organic Molecule, Ministry of Education andKey Laboratory of Green Chemistry, Jiangxi Province, Nanchang, Jiangxi 330022, China

Supporting Information

General experimental methods:	2
General experimental procedure:	2
The reactions of quinazoline-3-oxide and 1,4-dioxane in various of solvents The KIE studies on ethers:	
¹ H and ¹³ C NMR spectra of compounds	
¹ H of spectra of benzoic acid concomitancy with 3q	

General experimental methods:


Unless otherwise stated, all commercial reagents were used as received. All solvents were dried and distilled according to standard procedures. Flash column chromatography was performed using silica gel (60-Å pore size, 32-63µm, standard grade). Analytical thin–layer chromatography was performed using glass plates precoated with 0.25 mm 230-400 mesh silica gel impregnated with a fluorescent indicator (254 nm). Thin layer chromatography plates were visualized by exposure to ultraviolet light. Organic solutions were concentrated on rotary evaporators at ~20 Torr at 25-35°C. Nuclear magnetic resonance (NMR) spectra are recorded in parts per million from internal tetramethylsilane on the δ scale. ¹H and ¹³C NMR spectra were recorded in CDCl₃ on a Bruker DRX-400 spectrometer operating at 400 MHz and 100 MHz, respectively. All chemical shift values are quoted in ppm and coupling constants quoted in Hz. High resolution mass spectrometry (HRMS) spectra were obtained on a micrOTOF II Instrument.

General experimental procedure


A Schlenk tube was charged withquinazoline 3-oxide 1 (0.20 mmol) and *t*-butyl peroxybenzoate (TBPB, 0.2 mmol, 1.0 equiv.) under N₂. Then 1,4-dioxane 2a(1.0 mL) was injected into the bottom of the tube using a long needle syringe. The mixture was stirred at 100 °C for 4.5 h. After completion of the reaction (monitored by TLC), Et₃N (2.0 mL) was added to remove the benzoic acid. Then, the mixture was concentrated in vacuum and the residue was purified by flash column chromatography on silica gel with petroleum ether-ethyl acetate as eluent to give the desired product.

The reactions of quinazoline-3-oxide and 1,4-dioxane in various of solvents


Screening of the solvents revealed that the reaction could be performed at a loading of 10 equivalents 2a in PhCl (entry 2), but the yield was lowered to 25%.



^a Reaction conditions: 1a (0.2 mmol), 2a (10.0 equiv), solvent 1.0mL, under N₂, sealed tube. ^b Isolated yield.




In a Schlenk tube, the mixture of 1a (0.2 mmol), 1,4-dioxane and 1,4-dioxane-d₈ (1:1, 1.0 mL) was treated by standard condition for 4.5 h. After completion of the reaction, Et₃N (2.0 mL) was added to remove the benzoic acid. Then, the mixture was concentrated in vacuum and the residue was purified by flash column chromatography on silica gel with petroleum ether-ethyl acetate as eluent to give product **3a** and **3a**-d₇. The mixture was analyzed using ¹H NMR spectrometer. The data analysis method is explained as follows:




The 1,4-dioxane part of 3a-d₇ are silent on ¹H NMR while that of 3a are responding. So the ether proton adjacent toquinazoline skeleton was integrated as 1.00. Both 3a and 3a-d₇ have signal in the region of 7.28–8.85 ppm. The ratio of 3a / 3a-d7 was calculated to be 1/(1.29-1) = 1/0.29 = 3.4.


Characterization data for the cross-coupled products:




4-(1,4-dioxan-2-yl)-2-(p-tolyl)quinazoline 3-oxide (3a). Compound was obtained as a faint yellow solid: yield 76%;¹H NMR (400 MHz, CDCl₃) δ 8.84 (d, *J* = 8.8 Hz, 1H), 8.18 (d, *J* = 8.4 Hz, 2H), 7.99 (d, *J* = 8.0 Hz, 1H), 7.77 – 7.67 (m, 1H), 7.62 – 7.55 (m, 1H), 7.31 (d, *J* = 8.4 Hz, 2H), 6.10 (dd, *J* = 9.6, 2.8 Hz, 1H), 4.25 (dd, *J* = 11.2, 2.4 Hz, 1H), 4.10 (d, *J* = 10.8 Hz, 1H), 4.05 – 3.90 (m, 3H), 3.77 (t, *J* = 10.8, 1H), 2.43 (s, 3H).¹³C NMR (101 MHz, CDCl₃) δ 154.3, 149.8, 141.3, 140.9, 131.1, 130.3, 130.0, 129.3, 129.1, 128.7, 128.5, 128.3, 124.3, 122.8, 75.2, 67.6, 67.0, 66.6, 21.6.HRMS (ESI): m/z [M + H]⁺ calcd for C₁₉H₁₈N₂O₃: 323.1396, found 323.1397.




4-(1,4-dioxan-2-yl)-2-(m-tolyl)quinazoline 3-oxide (3b). Compound was obtained as a faint yellow solid: yield 78%;¹H NMR (400 MHz, CDCl₃) δ 8.86 (d, *J* = 8.4 Hz, 1H), 8.10 – 7.95 (m, 3H), 7.76-7.69 (m, 1H), 7.64-7.56 (m, 1H), 7.40 (t, *J* = 7.6 Hz, 1H), 7.34 (d, *J* = 7.6 Hz, 1H), 6.10 (dd, *J* = 9.6, 2.6 Hz, 1H), 4.26 (dd, *J* = 11.2, 2.4 Hz, 1H), 4.11 (d, *J* = 11.2 Hz, 1H), 4.07 – 3.88 (m, 3H), 3.77 (t, *J* = 10.0, 1H), 2.45 (s, 3H).¹³C NMR (101 MHz, CDCl₃) δ 154.5, 149.8, 140.9, 137.7, 132.1, 131.7, 131.2, 130.7, 129.1, 128.7, 127.9, 127.4, 124.3, 123.0, 75.2, 67.6, 67.0, 66.6, 21.5.HRMS (ESI): m/z [M + H]⁺ calcd for C₁₉H₁₈N₂O₃: 323.1396, found 323.1394.




4-(1,4-dioxan-2-yl)-2-(o-tolyl)quinazoline 3-oxide(3c). Compound was obtained as a white solid: yield 71%;¹H NMR (400 MHz, CDCl₃) δ 8.90 (d, *J* = 8.4 Hz, 1H), 8.01 (d, *J* = 8.4 Hz, 1H), 7.75 (t, *J* = 7.6 Hz, 1H), 7.66 (t, *J* = 7.8 Hz, 1H), 7.49 (d, *J* = 7.2 Hz, 1H), 7.42 (t, *J* = 7.4 Hz, 1H), 7.33 (t, *J* = 7.2 Hz, 2H), 6.06 (dd, *J* = 9.6, 2.4 Hz, 1H), 4.24 (dd, *J* = 11.2, 2.0 Hz, 1H), 4.11 (d, *J* = 11.2 Hz, 1H), 4.06 – 3.89 (m, 3H), 3.79 (t, *J* = 10.4 Hz, 1H), 2.27 (s, 3H).¹³C NMR (101 MHz, CDCl₃) δ 156.5, 149.2, 140.4, 137.4, 132.8, 131.2, 130.3, 130.0, 129.2, 129.1, 129.0, 125.9, 124.3, 123.2, 75.0, 67.6, 67.0, 66.6, 19.5.HRMS (ESI): m/z [M + H]⁺ calcd for C₁₉H₁₈N₂O₃: 323.1396, found 323.1397.




4-(1,4-dioxan-2-yl)-2-(4-methoxyphenyl)quinazoline 3-oxide(3d). Compound was obtained as afaint yellow solid: yield 75%;¹H NMR (400 MHz, CDCl₃) δ 8.85 (d, *J* = 8.8 Hz, 1H), 8.37 (d, *J* = 8.8 Hz, 2H), 7.99 (d, *J* = 8.4 Hz, 1H), 7.72 (t, *J* = 7.6 Hz, 1H), 7.59 (t, *J* = 7.8 Hz, 1H), 7.02 (d, *J* = 8.8 Hz, 2H), 6.11 (dd, *J* = 9.6, 2.4 Hz, 1H), 4.27 (dd, *J* = 11.2, 2.4 Hz, 1H), 4.11 (d, *J* = 11.2 Hz, 1H), 4.02-3.96 (m, 3H), 3.89 (s, 3H), 3.77 (t, *J* = 10.4 Hz, 1H).¹³C NMR (101 MHz, CDCl₃) δ 161.8, 153.7, 150.0, 141.1, 132.4, 131.3, 129.0, 128.3, 124.4, 124.3, 122.6, 113.4, 75.2, 67.6, 67.1, 66.6, 55.5.HRMS (ESI): m/z [M + H]⁺ calcd for C₁₉H₁₈N₂O₄: 339.1345, found 339.1347.




4-(1,4-dioxan-2-yl)-2-(4-fluorophenyl)quinazoline 3-oxide (**3e**). Compound was obtained as afaint yellow solid: yield 78%;¹H NMR (400 MHz, CDCl₃) δ 8.86 (d, *J* = 8.8 Hz, 1H), 8.36 (dd, *J* = 8.8, 5.6 Hz, 2H), 8.00 (d, *J* = 8.4 Hz, 1H), 7.74 (t, *J* = 7.6 Hz, 1H), 7.62 (t, *J* = 7.8 Hz, 1H), 7.19 (t, *J* = 8.6 Hz, 2H), 6.09 (dd, *J* = 9.6, 2.6 Hz, 1H), 4.25 (dd, *J* = 11.2, 2.6 Hz, 1H), 4.12 (d, *J* = 11.2 Hz, 1H), 4.06 – 3.91 (m, 3H), 3.77 (t, *J* = 10.6 Hz, 1H).¹³C NMR (101 MHz, CDCl₃) δ 164.3 (d, *J* = 250.6 Hz), 153.1, 150.1, 140.9, 132.9 (d, *J* = 8.7 Hz), 131.4, 129.1, 128.8, 128.2 (d, *J* = 3.4 Hz), 124.4, 122.9, 115.1 (d, *J* = 21.7 Hz), 75.1, 67.6, 67.0, 66.6.HRMS (ESI): m/z [M + H]⁺ calcd for C₁₈H₁₅FN₂O₃: 327.1145, found 327.1146.




2-(4-chlorophenyl)-4-(1,4-dioxan-2-yl)quinazoline 3-oxide (**3f**). Compound was obtained as ayellow solid: yield 70%; ¹H NMR (400 MHz, CDCl₃) δ 8.86 (d, *J* = 8.4 Hz, 1H), 8.30 (d, *J* = 8.8 Hz, 2H), 7.99 (d, *J* = 8.4 Hz, 1H), 7.73 (t, *J* = 7.6 Hz, 1H), 7.62 (t, *J* = 7.6 Hz, 1H), 7.47 (d, *J* = 8.8 Hz, 2H), 6.08 (dd, *J* = 9.6, 2.4 Hz, 1H), 4.24 (dd, *J* = 11.1, 2.4 Hz, 1H), 4.11 (d, *J* = 11.2 Hz, 1H), 4.05 – 3.90 (m, 3H), 3.76 (t, *J* = 10.4, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 153.0, 150.0, 140.8, 137.1, 131.9, 131.3, 130.6, 129.1, 128.9, 128.2, 124.3, 123.0, 75.1, 67.6, 67.0, 66.6.HRMS (ESI): m/z [M + H]⁺ calcd for C₁₈H₁₅ClN₂O₃: 343.0849, found 343.0850.




2-(3-chlorophenyl)-4-(1,4-dioxan-2-yl)quinazoline 3-oxide(3g). Compound was obtained as a faint yellow solid: yield 70%;¹H NMR (400 MHz, CDCl₃) δ 8.87 (d, *J* = 8.4 Hz, 1H), 8.31 (s, 1H), 8.20 (d, *J* = 7.6 Hz, 1H), 8.01 (d, *J* = 8.4 Hz, 1H), 7.75 (t, *J* = 7.8 Hz, 1H), 7.64 (t, *J* = 7.8 Hz, 1H), 7.54-7.48 (m, 1H), 7.44 (t, *J* = 7.8 Hz, 1H), 6.08 (dd, *J* = 9.6, 2.8 Hz, 1H), 4.24 (dd, *J* = 11.2, 2.4 Hz, 1H), 4.12 (d, *J* = 10.4 Hz, 1H), 4.07 – 3.92 (m, 3H), 3.77 (t, *J* = 10.4 Hz, 1H).¹³C NMR (101 MHz, CDCl₃) δ 152.7, 150.1, 140.8, 134.0, 133.8, 131.4, 131.0, 130.4, 129.2, 129.1, 128.6, 124.4, 123.1, 75.1, 67.6, 67.0, 66.6.HRMS (ESI): m/z [M + H]⁺ calcd for C₁₈H₁₅ClN₂O₃: 343.0849, found 343.0849.




2-(4-bromophenyl)-4-(1,4-dioxan-2-yl)quinazoline 3-oxide (3h). Compound was obtained as ayellow solid: yield 60%;¹H NMR (400 MHz, CDCl₃) δ 8.85 (d, *J* = 8.4 Hz, 1H), 8.22 (d, *J* = 8.4 Hz, 2H), 7.99 (d, *J* = 8.4 Hz, 1H), 7.73 (t, *J* = 7.4 Hz, 1H), 7.67-7.57 (m, 3H), 6.07 (dd, *J* = 9.6, 2.8 Hz, 1H), 4.24 (dd, *J* = 11.2, 2.4 Hz, 1H), 4.11 (d, *J* = 11.2 Hz, 1H), 4.05 – 3.90 (m, 3H), 3.76 (t, *J* = 10.6, 1H).¹³C NMR (101 MHz, CDCl₃) δ 153.1, 150.0, 140.8, 132.0, 131.3, 131.2, 131.1, 129.2, 128.9, 125.6, 124.4, 123.0, 75.1, 67.6, 67.0, 66.6.HRMS (ESI): m/z [M + H]⁺ calcd for C₁₈H₁₅BrN₂O₃: 387.0344, found 387.0343.




4-(1,4-dioxan-2-yl)-2-(4-(trifluoromethyl)phenyl)quinazoline 3-oxide(3i). Compound was obtained as ayellow solid: yield 77%;¹H NMR (400 MHz, CDCl₃) δ 8.90 (d, *J* = 8.4 Hz, 1H), 8.40 (d, *J* = 8.0 Hz, 2H), 8.03 (d, *J* = 8.4 Hz, 1H), 7.80-7.73 (m, 3H), 7.69-7.63 (m, 1H), 6.09 (dd, *J* = 9.6, 2.8 Hz, 1H), 4.25 (dd, *J* = 11.2, 2.4 Hz, 1H), 4.12 (d, *J* = 10.8 Hz, 1H), 4.07 – 3.90 (m, 3H), 3.78 (t, *J* = 10.4,1H).¹³C NMR (101 MHz, CDCl₃) δ 152.9, 150.4, 141.0, 135.7, 132.4 (q, ²*J* = 33.1 Hz), 131.7, 130.9, 129.4, 128.4, 125.0 (q, ³*J* = 3.7 Hz), 124.6, 124.0 (q, *J* = 270.9 Hz), 123.3, 75.2, 67.7, 67.1, 66.7..HRMS (ESI): m/z [M + H]⁺ calcd for C₁₉H₁₅F₃N₂O₃: 377.1113, found 377.1100.




4-(1,4-dioxan-2-yl)-2-(4-nitrophenyl)quinazoline 3-oxide (3j). Compound was obtained as ayellow solid: yield 50%;¹H NMR (400 MHz, CDCl₃) δ 8.93 (d, *J* = 8.4 Hz, 1H), 8.21 (d, *J* = 8.0 Hz, 1H), 8.02 (d, *J* = 8.4 Hz, 1H), 7.85 – 7.64 (m, 5H), 5.96 (dd, *J* = 9.6, 2.4 Hz, 1H), 4.15 (dd, *J* = 11.2, 2.2 Hz, 1H), 4.09 (d, *J* = 10.0 Hz, 1H), 4.01-3.87 (m, 3H), 3.73 (t, *J* = 10.4 Hz, 1H).¹³C NMR (101 MHz, CDCl₃) δ 153.8, 149.0, 148.6, 140.9, 134.0, 131.9, 131.5, 131.1, 129.4, 129.1, 128.1, 124.8, 123.9, 123.4, 74.9, 67.5, 66.9, 66.6.HRMS (ESI): m/z [M + H]⁺ calcd for C₁₈H₁₅N₃O₅: 354.1090, found 354.1090.




4-(1,4-dioxan-2-yl)-2-phenylquinazoline 3-oxide(3k). Compound was obtained as ayellow solid: yield 80%;¹H NMR (400 MHz, CDCl₃) δ 8.86 (d, *J* = 8.4 Hz, 1H), 8.29 – 8.20 (m, 2H), 8.01 (d, *J* = 8.4 Hz, 1H), 7.76 – 7.69 (m, 1H), 7.66 – 7.57 (m, 1H), 7.56 – 7.45 (m, 3H), 6.10 (dd, *J* = 9.6, 2.8 Hz, 1H), 4.25 (dd, *J* = 11.2, 2.8 Hz, 1H), 4.11 (d, *J* = 11.2 Hz, 1H), 4.05 – 3.90 (m, 3H), 3.77 (t, *J* = 10.4, 1H).¹³C NMR (101 MHz, CDCl₃) δ 154.2, 149.8, 140.9, 132.2, 131.2, 130.9, 130.3, 129.2, 128.8, 128.0, 124.3, 123.0, 75.1, 67.6, 67.0, 66.6.HRMS (ESI): m/z [M + H]⁺ calcd for C₁₈H₁₆N₂O₃: 309.1239, found 309.1240.




4-(1,4-dioxan-2-yl)-2-ethylquinazoline 3-oxide (3l). Compound was obtained as ayellow solid: yield 74%;¹H NMR (400 MHz, CDCl₃) δ 8.80 (d, *J* = 8.4 Hz, 1H), 7.94 (d, *J* = 8.4 Hz, 1H), 7.70 (t, *J* = 8.0Hz, 1H), 7.57 (t, *J* = 7.8 Hz, 1H), 6.07 (dd, *J* = 9.6, 2.8 Hz, 1H), 4.19 (dd, *J* = 11.2, 2.4 Hz, 1H), 4.09 (d, *J* = 10.8 Hz, 1H), 4.04 – 3.90 (m, 3H), 3.76 (t, *J* = 10.4Hz, 1H), 3.31-3.18 (m, 1H), 1.44 (t, *J* = 7.4 Hz, 3H).¹³C NMR (101 MHz, CDCl₃) δ 159.9, 148.1, 140.3, 130.8, 128.6, 128.0, 124.3, 122.5, 77.4, 77.1, 76.8, 74.8, 67.5, 66.9, 66.6, 25.6, 9.9.HRMS (ESI): m/z [M + H]⁺ calcd for C₁₄H₁₆N₂O₃: 261.1239, found 261.1236.




4-(1,4-dioxan-2-yl)quinazoline 3-oxide (3m). Compound was obtained as a white solid: yield 54%;¹H NMR (400 MHz, CDCl₃) δ 8.93 (s, 1H), 8.84 (d, *J* = 8.4 Hz, 1H), 7.98 (d, *J* = 8.4 Hz, 1H), 7.79 – 7.72 (m, 1H), 7.71 – 7.63 (m, 1H), 6.02 (dd, *J* = 9.8, 2.8 Hz, 1H), 4.19 (dd, *J* = 11.2, 2.8 Hz, 1H), 4.10 (d, *J* = 10.8 Hz, 1H), 4.04 – 3.90 (m, 3H), 3.74 (t, *J* = 10.4, Hz, 1H).¹³C NMR (101 MHz, CDCl₃) δ 148.4, 147.1, 141.2, 131.3, 129.5, 129.1, 124.8, 123.1, 74.3, 67.5, 66.9, 66.6.HRMS (ESI): m/z [M + H]⁺ calcd for C₁₂H₁₂N₂O₃: 233.0926, found 233.0926.




4-(1,4-dioxan-2-yl)-7-methyl-2-(p-tolyl)quinazoline 3-oxide (**3n**). Compound was obtained as a light yellow solid: yield 71%; ¹H NMR (400 MHz, CDCl₃) δ 8.73 (d, *J* = 8.8 Hz, 1H), 8.19 (d, *J* = 8.0 Hz, 2H), 7.78 (s, 1H), 7.42 (d, *J* = 8.8 Hz, 1H), 7.30 (d, *J* = 8.0 Hz, 2H), 6.09 (dd, *J* = 9.6, 2.8 Hz, 1H), 4.25 (dd, *J* = 11.2, 2.4 Hz, 1H), 4.10 (d, *J* = 11.2 Hz, 1H), 4.05 – 3.89 (m, 3H), 3.74 (t, *J* = 10.4,1H), 2.54 (s, 3H), 2.43 (s, 3H).¹³C NMR (101 MHz, CDCl₃) δ 154.2, 149.7, 142.0, 142.3,141.2, 130.7, 130.3, 129.5, 128.6, 128.2, 123.9, 120.9, 75.2, 67.6, 67.1, 66.6, 21.8, 21. HRMS (ESI): m/z [M + H]⁺ calcd for C₂₀H₂₀N₂O₃: 337.1552, found 337.1556.




4-(1,4-dioxan-2-yl)-6-methoxy-2-(p-tolyl)quinazoline 3-oxide(3o).Compound was obtained as a light yellow solid: yield 68%; ¹H NMR (400 MHz, CDCl₃) δ 8.16 (d, *J* = 8.0 Hz, 3H), 7.89 (d, *J* = 9.2 Hz, 1H), 7.35 (dd, *J* = 9.2, 2.8 Hz, 1H), 7.29 (d, *J* = 8.0 Hz, 2H), 6.10 (dd, *J* = 9.6, 2.4 Hz, 1H), 4.24 (dd, *J* = 11.2, 2.4 Hz, 1H), 4.09 (d, *J* = 11.6 Hz, 1H), 4.05-3.99 (m, 1H), 3.96 (s, 3H), 3.93-3.85 (m, 2H), 3.77 (t, *J* = 10.4 Hz, 1H), 2.42 (s, 3H).¹³C NMR (101 MHz, CDCl₃) δ 158.9, 152.3, 148.3, 140.9, 137.0, 130.5, 130.1, 129.5, 128.6, 124.1, 123.1, 102.7, 75.1, 67.61, 66.74, 66.69, 55.6, 21.5.HRMS (ESI): m/z [M + H]⁺ calcd for C₂₀H₂₀N₂O₄: 353.1501, found 353.1499.




4-(1,4-dioxan-2-yl)-2-(p-tolyl)-7-(trifluoromethyl)quinazoline 3-oxide (**3p**). Compound was obtained as ayellow oil liquid: yield 77%; ¹H NMR (400 MHz, CDCl₃) δ 8.98 (d, *J* = 8.8 Hz, 1H), 8.28 (s, 1H), 8.22 (d, *J* = 8.4 Hz, 2H), 7.74 (d, *J* = 9.2 Hz, 1H), 7.32 (d, *J* = 8.4 Hz, 2H), 6.03 (dd, *J* = 9.6, 2.4 Hz, 1H), 4.26 (dd, *J* = 11.2, 2.4 Hz, 1H), 4.12 (d, *J* = 10.8 Hz, 1H), 4.06 – 3.90 (m, 3H), 3.71 (t, *J* = 10.6, 1H), 2.45 (s, 3H).¹³C NMR (101 MHz, CDCl₃) δ 155.5, 149.7, 142.0, 139.7, 132.3 (q, ²*J* = 33.0 Hz), 130.4, 128.8, 128.6, 126.6 (q, ³*J* = 4.4 Hz),125.5, 124.4, 124.1 (q, ³*J* = 3.0 Hz), 123.4 (q, ¹*J* = 270.9 Hz),75.2, 67.6, 66.9, 66.6, 21.6.HRMS (ESI): m/z [M + H]⁺ calcd for C₂₀H₁₇F₃N₂O₃: 391.1270, found 391.1266.



6-chloro-4-(1,4-dioxan-2-yl)-2-(p-tolyl)quinazoline 3-oxide(3q). Compound was obtained as ayellow solid: yield 82%;¹H NMR (400 MHz, CDCl₃) δ 8.82 (d, *J* = 2.0 Hz, 1H), 8.18 (d, *J* = 8.0 Hz, 2H), 7.91 (d, *J* = 8.8 Hz, 1H), 7.63 (dd, *J* = 8.8, 2.4 Hz, 1H), 7.31 (d, *J* = 8.0 Hz, 2H), 6.01 (dd, *J* = 9.6, 2.8 Hz, 1H), 4.25 (dd, *J* = 11.2, 2.8 Hz, 1H), 4.14 (d, *J* = 9.6 Hz, 1H), 4.04 – 3.91 (m, 3H), 3.70 (t, *J* = 10.4 Hz, 1H), 2.43 (s, 3H).¹³C NMR (101 MHz, CDCl₃) δ 154.4, 148.9, 141.7, 139.1, 134.4, 131.7, 130.5, 130.3, 128.9, 128.7, 123.5, 123.0, 75.3, 67.6, 66.8, 66.6, 21.6.HRMS (ESI): m/z [M + H]⁺ calcd for C₁₉H₁₇ClN₂O₃: 357.1006, found 357.1005.




6-bromo-4-(1,4-dioxan-2-yl)-2-(p-tolyl)quinazoline 3-oxide(3r). Compound was obtained as ayellow solid: yield 53%;¹H NMR (400 MHz, CDCl₃) δ 8.99 (d, *J* = 2.0 Hz, 1H), 8.18 (d, *J* = 8.4 Hz, 2H), 7.84 (d, *J* = 8.8 Hz, 1H), 7.76 (dd, *J* = 9.0, 2.2 Hz, 1H), 7.31 (d, *J* = 8.4 Hz, 2H), 6.00 (dd, *J* = 9.6, 2.4 Hz, 1H), 4.25 (dd, *J* = 11.2, 2.8 Hz, 1H), 4.14 (d, *J* = 9.6 Hz, 1H), 4.04 – 3.89 (m, 3H), 3.70 (t, *J* = 10.0, 1H), 2.43 (s, 3H).¹³C NMR (101 MHz, CDCl₃) δ 154.5, 148.8, 141.7, 139.3, 134.3, 130.6, 130.3, 128.9, 128.7, 126.2, 123.9, 122.7, 75.3, 67.6, 66.8, 66.6, 21.6.HRMS (ESI): m/z [M + H]⁺ calcd for C₁₉H₁₇BrN₂O₃: 401.0501, found 401.0498.




6-bromo-2-(4-bromophenyl)-4-(1,4-dioxan-2-yl)quinazoline 3-oxide(3s).


Compound was obtained as ayellow solid: yield 67%;¹H NMR (400 MHz, CDCl₃) δ 9.00 (d, *J* = 2.0 Hz, 1H), 8.21 (d, *J* = 8.8 Hz, 2H), 7.84 (d, *J* = 8.8 Hz, 1H), 7.78 (dd, *J* = 8.8, 2.0 Hz, 1H), 7.63 (d, *J* = 8.8 Hz, 2H), 5.98 (dd, *J* = 9.6, 2.8 Hz, 1H), 4.23 (dd, *J* = 11.2, 2.4 Hz, 1H), 4.14 (d, *J* = 9.2 Hz, 1H), 4.04 – 3.89 (m, 3H), 3.69 (t, *J* = 10.0, Hz, 1H).¹³C NMR (101 MHz, CDCl₃) δ 153.3, 149.1, 139.2, 134.7, 132.0, 131.3, 130.6, 126.4, 126.0, 124.1, 123.3, 75.2, 67.6, 66.8, 66.6.HRMS (ESI): m/z [M + H]⁺ calcd for C₁₈H₁₄Br₂N₂O₃: 464.9449, found 464.9448.




4-(1,4-dioxan-2-yl)-6,7-dimethoxyquinazoline 3-oxide(3t).Compound was obtained as a white solid: yield 59%; ¹H NMR (400 MHz, CDCl₃) δ 8.87 (s, 1H), 8.18 (s, 1H), 7.28 (s, 1H), 6.05 (dd, *J* = 9.8, 2.6 Hz, 1H), 4.23 (dd, *J* = 11.8, 2.6 Hz, 1H), 4.04 (s, 6H), 4.02 – 3.92 (m, 2H), 3.89-3.84 (m, 1H), 3.70 (t, *J* = 10.6 Hz, 1H).¹³C NMR (101 MHz, CDCl₃) δ 153.8, 151.3, 147.2, 145.4, 139.6, 119.1, 107.8, 102.7, 74.3, 67.6, 66.9, 66.7, 56.4, 56.1.HRMS (ESI): m/z [M + H]⁺ calcd for C₁₄H₁₆N₂O₅: 293.1137, found 293.1136.




4-(1,3-dioxolan-2-yl)-2-(p-tolyl)quinazoline 3-oxide (3u). Compound was obtained as ayellow solid: yield 65%;¹H NMR (400 MHz, CDCl₃) δ 8.38 (d, *J* = 8.8 Hz, 1H), 8.21 (d, *J* = 8.4 Hz, 2H), 7.98 (d, *J* = 8.0 Hz, 1H), 7.73-7.64 (m, 1H), 7.62-7.53 (m, 1H), 7.31 (d, *J* = 8.0 Hz, 2H), 6.88 (s, 1H), 4.43-4.31 (m, 2H), 4.27-4.13 (m, 2H), 2.43 (s, 3H).¹³C NMR (101 MHz, CDCl₃) δ 154.9, 147.0, 141.3, 140.7, 130.9, 130.4, 129.2, 129.1, 129.0, 128.6, 123.0, 122.3, 98.8, 65.6, 21.6.HRMS (ESI): m/z [M + H]⁺ calcd for C₁₈H₁₆N₂O₃: 309.1239, found 309.1242.




4-(benzo[d][1,3]dioxol-2-yl)-2-(p-tolyl)quinazoline 3-oxide (3v). Compound was obtained as a white solid: yield 51%;¹H NMR (400 MHz, CDCl₃) δ 8.26 (d, *J* = 8.4 Hz, 2H), 8.05 (s, 1H), 8.02 (d, *J* = 8.8 Hz, 2H), 7.68 (t, *J* = 7.8 Hz, 1H), 7.49 (t, *J* = 8.0, 1H), 7.33 (d, *J* = 8.0 Hz, 2H), 7.04 – 6.92 (m, 4H), 2.45 (s, 3H).¹³C NMR (101 MHz, CDCl₃) δ 154.7, 146.8, 145.4, 141.7, 140.7, 131.1, 130.5, 129.7, 129.4, 128.8, 122.7, 122.2, 121.9, 109.4, 104.7, 21.7.HRMS (ESI): m/z [M + H]⁺ calcd for C₂₂H₁₆N₂O₃: 356.1239, found 357.1237.




4-(1,2-dimethoxyethyl)-2-(p-tolyl)quinazoline 3-oxide(3w). Compound was obtained as a yellow liquid: yield 41%;¹H NMR (400 MHz, CDCl₃) δ 8.77 (d, *J* = 8.8 Hz, 1H), 8.21 (d, *J* = 8.0 Hz, 2H), 8.01 (d, *J* = 8.4 Hz, 1H), 7.73 (t, *J* = 7.8 Hz, 1H), 7.60 (t, *J* = 7.6 Hz, 1H), 7.32 (d, *J* = 8.0 Hz, 2H), 5.92 (dd, *J* = 6.4, 2.8 Hz, 1H), 4.03 (dd, *J* = 10.8, 6.4 Hz, 1H), 3.81 (dd, *J* = 10.8, 2.8 Hz, 1H), 3.45 (s, 3H), 3.43 (s, 3H),2.44 (s, 3H).¹³C NMR (100 MHz, CDCl₃) δ 154.5, 151.2, 141.3, 140.7, 131.2, 130.4, 129.3, 129.0, 128.9, 128.7, 128.3, 124.0, 123.1, 79.0, 72.2, 59.3, 58.6, 21.6.HRMS (ESI): m/z [M + H]⁺ calcd for C₁₉H₂₀N₂O₃: 325.1552, found 325.1552.



4-(diethoxymethyl)-2-(p-tolyl)quinazoline 3-oxide(3x). Compound was obtained as a white solid: yield 15%;¹H NMR (400 MHz, CDCl₃) δ 8.67 (d, *J* = 8.8 Hz, 1H), 8.17 (d, *J* = 8.0 Hz, 2H), 7.97 (d, *J* = 8.4 Hz, 1H), 7.72-7.68 (m, 1H), 7.59 (t, *J* = 7.6 Hz, 1H), 7.31 (d, *J* = 8.0 Hz, 2H), 6.80 (s, 1H), 3.95-4.03 (m, 2H), 3.78-3.71 (m, 2H), 2.43 (s, 3H), 1.28 (t, *J* = 7.0 Hz, 6H).¹³C NMR (101 MHz, CDCl₃) δ 154.6, 141.3, 141.2, 131.2, 130.3, 129.5, 128.7, 128.6, 128.6, 125.2, 121.6, 100.0, 98.3, 65.3, 21.6, 15.4.HRMS (ESI): m/z [M + H]⁺ calcd for C₂₀H₂₂N₂O₃: 339.1709, found 339.1701.





4-(1-(ethoxymethoxy)ethyl)-2-(p-tolyl)quinazoline 3-oxide(3x'). Compound was obtained as ayellow solid: yield 32%;¹H NMR (400 MHz, CDCl₃) δ 8.69 (d, *J* = 8.8 Hz, 1H), 8.23 (d, *J* = 8.4 Hz, 2H), 8.00 (d, *J* = 8.4 Hz, 1H), 7.74 – 7.66 (m, 1H), 7.62 – 7.55 (m, 1H), 7.31 (d, *J* = 8.0 Hz, 2H), 6.16 (q, *J* = 6.8 Hz, 1H), 4.79 (d, *J* = 6.8 Hz, 1H), 4.68 (d, *J* = 6.8 Hz, 1H), 3.61-3.53 (m, 1H), 3.43-3.35 (m, 1H), 2.43 (s, 3H), 1.75 (d, *J* = 6.8 Hz, 3H), 0.99 (t, *J* = 7.0 Hz, 3H).¹³C NMR (101 MHz, CDCl₃) δ 155.0, 154.5, 141.2, 140.9, 130.8, 130.4, 129.5, 129.2, 128.6, 128.4, 123.9, 122.0, 95.2, 70.7, 64.1, 21.6, 19.3, 14.9.HRMS (ESI): m/z [M + H]⁺ calcd for C₂₀H₂₂N₂O₃: 339.1709, found 339.1709.





4-(1-ethoxyethyl)-2-(p-tolyl)quinazoline 3-oxide(3y). Compound was obtained as ayellow solid: yield 91%;¹H NMR (400 MHz, CDCl₃) δ 8.84 (d, *J* = 8.8 Hz, 1H), 8.23 (d, *J* = 8.4 Hz, 2H), 8.01 (d, *J* = 8.4 Hz, 1H), 7.77 - 7.66 (m, 1H), 7.60-7.57 (m, 1H), 7.32 (d, *J* = 8.0 Hz, 2H), 5.89 (q, *J* = 6.8 Hz, 1H), 3.60-3.53 (m, 1H), 3.48-3.31 (m, 1H), 2.43 (s, 3H), 1.72 (d, *J* = 6.8 Hz, 3H), 1.21 (t, *J* = 7.0 Hz, 3H).¹³C NMR (101 MHz, CDCl₃) δ 155.3, 154.5, 141.2, 140.8, 131.0, 130.5, 129.5, 129.2, 128.6, 128.6, 123.5, 122.1, 73.1, 65.7, 21.6, 19.2, 15.3.HRMS (ESI): m/z [M + H]⁺ calcd for C₁₉H₂₀N₂O₂: 309.1603, found 309.1603.
















































































¹H of spectra of benzoic acid concomitancy with **3q.**